Summary: In a post hoc analysis of two randomised trials in Asian (predominantly Chinese) adults with type 2 diabetes suboptimally controlled on oral agents or basal insulin, the fixed-ratio combination iGlarLixi achieved larger 12-week HbA1c falls than insulin glargine 100 U/mL (LixiLan-O-AP -1.6% vs -1.1%; LixiLan-L-CN -1.3% vs -0.5%) and a shorter median time to target, driven mainly by postprandial glucose. The abstract reports no between-group p-values or confidence intervals, so these are descriptive, exploratory signals rather than confirmed efficacy.
PICO Summary
| Element | Detail |
|---|---|
| Population | Asian (predominantly Chinese) adults with type 2 diabetes suboptimally controlled on oral antidiabetic drugs (LixiLan-O-AP) or basal insulin with or without oral agents (LixiLan-L-CN); post hoc analysis pooling participants from two multicentre randomised controlled trials. |
| Intervention | iGlarLixi, a titratable fixed-ratio combination of insulin glargine and the GLP-1 receptor agonist lixisenatide, once daily. |
| Comparison | Insulin glargine 100 U/mL (Gla-100) once daily. |
| Outcome | Week 12 mean HbA1c reduction greater with iGlarLixi: LixiLan-O-AP -1.6% vs -1.1% (-17.0 vs -12.0 mmol/mol); LixiLan-L-CN -1.3% vs -0.5% (-13.9 vs -5.4 mmol/mol). Postprandial glucose reductions were greater with iGlarLixi; fasting plasma glucose reductions and hypoglycaemia incidence were similar between arms. Median time to HbA1c target was shorter with iGlarLixi (LixiLan-O-AP 85 vs 126 days; LixiLan-L-CN 85 vs 239 days), as was median time to postprandial-glucose target; time to fasting-glucose target was similar. The published abstract reports no between-group p-values, 95% CIs, ARR or NNT for these early-timepoint comparisons. |
iGlarLixi vs basal insulin: early control
Post hoc RCT · type 2 diabetes · 12 weeks
Across two randomised trials in Asian adults with type 2 diabetes, iGlarLixi produced larger 12-week HbA1c falls and faster time to target than insulin glargine, driven mainly by postprandial glucose. These are descriptive, post hoc signals reported without between-group p-values or confidence intervals.
Expert Commentary
The direction of these findings is unsurprising and biologically coherent: adding a prandial GLP-1 receptor agonist to basal insulin should blunt postprandial excursions and move patients to target faster than basal insulin alone, which is exactly the pattern observed. The verdict, however, must stay measured. This is a post hoc, descriptive analysis of two separate randomised trials, not a pre-specified efficacy endpoint, and the reported numbers are presented without between-group p-values, confidence intervals, absolute risk reductions or numbers needed to treat. The 12-week HbA1c separations are therefore best read as hypothesis-generating signals of earlier, postprandially driven control rather than as proven incremental efficacy. The single limitation that most constrains interpretation is the unblinded, open-label design inherited from the parent trials, compounded by analyses that were defined after the fact; selective timepoints and target definitions can flatter the combination product. Readers should also note that the study was conducted and authored substantially by the manufacturer of iGlarLixi, which warrants the usual caution about framing. Can I use this with my patients? Cautiously yes, for an Asian patient with type 2 diabetes whose fasting glucose is acceptable on basal insulin but whose HbA1c remains above target because of postprandial peaks, where a fixed-ratio basal-plus-GLP-1 step is a reasonable, guideline-consistent intensification. I would like to see the confirmatory between-group statistics and longer-term hypoglycaemia and tolerability data reported in full before treating the speed-to-target advantage as established.
References
Song L, Yuan X, Huang S, Zhang Y, Lauand F, Wang Z, et al. iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: a post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN studies. Diabetes Obes Metab. 2025;27(5):2593-2600. doi:10.1111/dom.16260